BTLA Antikörper (PE)

Produktnummer ABIN2663266

Der Maus Monoklonal Anti-BTLA-Antikörper wurde für FACS validiert. Er ist geeignet, BTLA in Proben von Maus zu detektieren.

Kurzübersicht für BTLA Antikörper (PE) (ABIN2663266)

Target: BTLA (B and T Lymphocyte Associated (BTLA))

Reaktivität: Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BTLA Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: 8F4

Produktdetails anti-BTLA Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu BTLA

Target: BTLA (B and T Lymphocyte Associated (BTLA))

Andere Bezeichnung: CD272

Hintergrund: B and T lymphocyte attenuator (BTLA) is an Ig superfamily coinhibitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand Herpes Virus Entry Mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, reduced effectiveness of T regulatory cells. BTLA takes an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significant up-regulated expression of BTLA compared with effector and naive T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It was reported that BTLA may regulate T cell function by binding to B7-H4. But further studies are needed to confirm. The existence of three distinct BTLA alleles was reported. The BTLA antibody reacts with mouse BTLA from both BALb/c and C57BL/6 strains.

Pathways: Cancer Immune Checkpoints